1. Pink Sheet
  2. >>Geography
  3. >>Europe

Advanced Therapy Developers Urged To Monitor Major EU Proposal On Using Blood, Tissues & Cells

 
• By Neena Brizmohun

Companies have the opportunity to tell the European Commission what they think about its proposed regulation that would overhaul the rules governing the use of substances of human origin.

Blood, tissues or cells may be used as starting materials for ATMPs • Source: Alamy

Companies developing advanced therapies are being advised to monitor developments surrounding a proposed EU regulation that seeks to improve the rules governing the use of substances of human origin (SoHOs). The proposal has been largely welcomed by industry.

The regulation, proposed by the European Commission, aims to strengthen the existing but outdated rules on the safety and quality...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

New EU Approvals

 
• By Neena Brizmohun

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include three new products, one of which is Rezdiffra, Madrigal Pharmaceuticals’s treatment for metabolic dysfunction-associated steatohepatitis.

MHRA Backs Global AI Framework For Pharmacovigilance Over UK-Specific Guidance

 
• By Vibha Sharma

The UK’s medicines regulator wants to ensure that guidance on the use of artificial intelligence in pharmacovigilance processes remains fit for the future.

Cosmo Wins Over EMA With Risk Minimizing Measures And Expert Advice For Winlevi

 
• By Neena Brizmohun

The European Medicines Agency says that Winlevi should be approved in the EU for treating acne, having previously turned the drug down.

Navigating Rare Disease Submissions: Minoryx Stresses Early EMA Engagement

 
• By Manas Mishra

Minoryx explained to Pink Sheet why it believes its resubmission for leriglitazone stands a stronger chance of approval, and highlighted the value of early dialogue with the regulators when it comes to rare diseases, where the understanding of the natural history and outcomes is often limited.

More from Geography

US FDA’s ARIA Analysis Adds Earlier Scan To Biogen/Eisai Leqembi Label

 
• By Bridget Silverman

Six deaths early in treatment inspired a new safety requirement for Biogen/Eisai’s Leqembi to promote early identification of patients affected by the well-known risk of amyloid-related imaging abnormalities with edema (ARIA-E).

COVID-19 Vaccines: Pfizer Arguments To Keep EUA Failed To Persuade US FDA’s Prasad

 
• By Sue Sutter

The CBER director rejected Pfizer’s assertions that pediatric dosing gaps, supply constraints and comparative mRNA content justify keeping the vaccine under emergency use authorization for younger children.

New US FDA AI Councils Will Focus On Internal, External Policy

 
• By Sarah Karlin-Smith

The agency is creating two new AI councils to facilitate its role in responsible AI adoption and regulation.